Skip to main content
ADCT logo

ADCT · ADC Therapeutics SA · Investor Relations

Track ADCT — free
$1.25 -0.05 (-3.78%) Q1 2026 earnings call transcript
Market Cap
$165.97M
Shares
127.67M
Volume · Nov 19 752.42K Avg daily vol (3M) 1.57M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-09 ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates
2026-11-04 ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
2026-11-03 ADC Therapeutics to Present at November Investor Conferences
2026-11-02 ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
2026-11-02 ADC Therapeutics Announces New Employee Inducement Grant
2026-10-29 ADC Therapeutics Announces ZYNLONTA® Updates in Japan
2026-10-13 ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
2026-08-13 ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
2026-06-24 ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA ® Growth Opportunities and Regulatory Priorities
2026-06-03 ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA ® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2026-05-04 ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
2026-03-10 ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
2026-01-08 ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
2025-11-10 ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

Past events

Source: https://ir.adctherapeutics.com/overview

Key facts CIK 1771910 CUSIP H0036K147 13F (30d) 116 filings 102 filers Visit website Investor relations